Sevgi B. Rodan

Baylor College of Medicine — United States

Medicine · Health Sciences

43h-index6.8kcitations92works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and treatments(33), Bone Metabolism and Diseases(29), Cell Adhesion Molecules Research(25), Inflammatory mediators and NSAID effects(13), Protein Kinase Regulation and GTPase Signaling(11)

Publications92 total

Abstract P4-19-03: Breast cancer oriented biobank and associated biobank management system: Preliminary analysis on 9043 samples from 274 individuals
Cancer Research·2013
Lawrence G. Raisz November 13, 1925–August 25, 2010
Journal of Bone and Mineral Research·2011· 1 cited
Cathepsin K - A Novel Molecular Target for Treatment of Osteoporosis: Discovery of Odanacatib
Bone·2010
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor
Bioorganic & Medicinal Chemistry Letters·2009· 24 citedOpen Access
Bone density, strength, and formation in adult cathepsin K (−/−) mice
Bone·2008· 145 cited
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Bioorganic & Medicinal Chemistry Letters·2008· 467 citedOpen Access
Cathepsin K – A new molecular target for osteoporosis
IBMS BoneKEy·2008· 40 cited
Involvement of αvβ3 integrins in osteoclast function
Journal of Bone and Mineral Metabolism·2007· 220 cited
Diversity of the Osteoblastic Phenotype
Novartis Foundation symposium·2007· 62 cited
Identification of a potent and selective non-basic cathepsin K inhibitor
Bioorganic & Medicinal Chemistry Letters·2006· 87 citedOpen Access
Design and Synthesis of Tri-Ring P<sub>3</sub> Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K
Journal of Medicinal Chemistry·2005· 94 citedOpen Access
Nonpeptide α<sub>v</sub>β<sub>3</sub> Antagonists: Identification of Potent, Chain‐Shortened 7‐Oxo RGD Mimetics.
ChemInform·2005
Nonpeptide αvβ3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics
Bioorganic & Medicinal Chemistry Letters·2005· 17 citedOpen Access
Erratum to “An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells” [Anal. Biochem. 335 (2004) 218–227]
Analytical Biochemistry·2005
An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells
Analytical Biochemistry·2004· 52 cited
Rational Design of Potent and Selective NH‐Linked Aryl/Heteroaryl Cathepsin K Inhibitors.
ChemInform·2004· 1 cited
Nonpeptide α<sub>v</sub>β<sub>3</sub> Antagonists. Part 11:  Discovery and Preclinical Evaluation of Potent α<sub>v</sub>β<sub>3</sub> Antagonists for the Prevention and Treatment of Osteoporosis
Journal of Medicinal Chemistry·2004· 79 citedOpen Access
Nonpeptide αvβ3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative
Bioorganic & Medicinal Chemistry Letters·2004· 14 cited
Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone
Bioorganic & Medicinal Chemistry Letters·2004· 14 citedOpen Access
Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors
Bioorganic & Medicinal Chemistry Letters·2004· 27 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Gideon A. Rodan(42), Gregg Wesolowski(20), Le T. Duong(8), Donald B. Kimmel(7), Chih‐Tai Leu(7), Jean‐Pierre Falgueyret(6), M. David Percival(6), George D. Hartman(6), Mark E. Duggan(6), Denis Riendeau(5), Renata M. Oballa(4), John Fisher(4), Rose Marie Nagy(4), Robert J. Majeska(3), Sylvie Desmarais(3), James T. Palmer(3), Robert N. Young(3), W. Cameron Black(3), Satoru Harada(3), Kenneth A. Thomas(3)